Catalyst

Slingshot members are tracking this event:

Infinity Announces Publication On PI3K-Gamma In Nature

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
INFI

100%

Additional Information

Additional Relevant Details  The paper, entitled "PI3K-gamma is a molecular switch that controls immune suppression,"1 describes research showing that targeting macrophage signaling pathways by inhibiting phosphoinositide-3-kinase (PI3K)-gamma may open the possibility to further improving and refining emerging immunotherapies that boost the body's own abilities to fight a range of diseases, including cancer. Infinity is conducting a Phase 1 clinical study of IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. IPI-549 is the only PI3K-gamma inhibitor in clinical development.
When confronted by pathogens, injury or disease, the initial response of the body's immune system comes in the form of macrophages, a type of white blood cell that express pro-inflammatory proteins called cytokines that, in turn, activate T cells, another immune cell, to attack the health threat. The macrophages then switch gears to express other cytokines that dampen T cell activation, stimulating tissue repair. In cancer, highly abundant macrophages express anti-inflammatory cytokines that induce immune suppression, leading to enhanced tumor growth.In the Nature paper, researchers pinpoint a key, suspected player: an enzyme in macrophages called PI3K-gamma. In mouse studies, they found that macrophage PI3K-gamma signaling promotes immune suppression by inhibiting activation of anti-tumor T cells. Blocking PI3K-gamma activated the immune response and significantly suppressed growth of implanted tumors in animal models. It also boosted sensitivity of some tumors to existing anti-cancer drugs and synergized with existing immune therapy to eradicate tumors. Researchers also identified a molecular signature of immune suppression and response in mice and cancer patients that may be used to track the effectiveness of immune therapy.
http://phx.corporate...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 19, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Pi3k-gamma, Immune Suppression, Acrophage Signaling Pathways, Phosphoinositide-3-kinase, Ipi-549